摘要
目的:考查莫昔沙星文拉法辛缓释剂联合喹硫平治疗精神分裂症阴性症状的疗效和不良反应。方法:采用入院顺序分层随机法,将80例慢性精神分裂症患者分为观察组(文拉法辛缓释剂联合喹硫平)和对照组(喹硫平),在治疗前和治疗第4、8、12周末以阳性和阴性症状量表(PNASS)总分及阴性因子分和不良反应量表(TESS)评定疗效和不良反应。结果:治疗12周末,观察组PANSS总分为(64.8±14.7),阴性因子分(30.2±3.2),与治疗前相比有统计学意义(P<0.01);对照组分别为(75.4±14.3)和(36.8±4.5),与治疗前比较有统计学意义(P<0.05),观察组阴性因子各项症状评分均低于对照组。两组患者出现药物不良反应差异无统计学意义(P>0.05)。结论:喹硫平治疗精神分裂症安全有效,协同文拉法辛治疗精神分裂症阴性症状可增加疗效。
Objective ： To study the efficacy and adverse drug reactions of the combined use of venlafaxine and quetiapine in the treatment of negative symptoms of schizophrenia. Methods ： eighty subjects with chronic schizophrenia were assigned to an investigational group and a control group by an admission - order - stratified random method. The subjects in the investigational group were given venlafaxine and quetiapine whereas subjects in the control group only quetiapine. Effects and adverse drug reactions in the two groups were evaluated with the score of negative and positive symptom scale（ PANSS）, negative symptom scale, and treatment emergent symptoms scale （TESS） respectively before and 4,8,12 weeks after the treatment. Results ： The PANSS scores and the negayive symptom scales of the investigational group at week 12 were （64.8 ± 14.7） and （30.2 ± 3.2） respectively, which were significantly lower than those before treatment with venlafaxine and quetiapine（ P 〈 0.01 ）. In control group, the PANSS scores and negayive symptom scales were （75.4 ±14.3 ） and （36.8 ± 4.5 ） respectively at the same time point, which were significantly lower than those before treatment with quediapine（P 〈 0.05 ）. The negative symptom scales of the investigational group were lower than those in control group. No significant difference in ADRs was found in the two groups （ P 〉 0.05 ）. Conclusion ： It is suggested that venlafaxine in combination with typical antipsychoties is effective and safe in the treatment of the negative symptom in schizophrenia.
出处
《天津药学》
2009年第3期37-39,共3页
Tianjin Pharmacy
